Development of subgroup-specific models of DIPG
In a recent publication in Nature Genetics, our group reported the results of a study of more than 70 DIPG tumours suggesting that this is not one disease, but rather three different diseases (MYCN, Silent & H3-K27M) driven by different genetic alterations or "hits".
This project aims to study the interaction between these genetic alterations in DIPG to determine which combination of changes is necessary for tumour formation in mice. In this way we can better understand which genetic alterations are driving tumour formation and growth and thus represent the best candidate drug targets. The development of new subgroup-specific mouse models will help us understand why current radiation and chemotherapeutic strategies are failing. They will also serve as useful preclinical models for testing promising, new therapies and set the stage for stratified, subgroup-tailored clinical trials.